Quest Diagnostics (DGX) Tops Q3 EPS by 10c; updates guidance

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.60, $0.10 better than the analyst estimate of $2.50. Revenue for the quarter came in at $2.82 billion versus the consensus estimate of $2.73 billion.

GUIDANCE:

Quest Diagnostics sees FY2025 EPS of $9.76-$8.84, versus the consensus of $9.75. Quest Diagnostics sees FY2025 revenue of $10.96-11 billion, versus the consensus of $10.869 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Barrick Is Said to Weigh Delaying North America Gold IPO to 2027 - Bloomberg
• Stria Lithium rebrands as Arc Mineral Royalties after gold deal
• White House: barrels from Venezuela deal could hit reserves in U.S. In November